Subscribe to RSS
Update on the etiology, classification, and management of glomerular diseases
Subject Editor: Financial support and sponsorship Nil.
In this brief review, the reader will find a timely update regarding some of the most commonly encountered glomerular diseases. The review will include an update on the etiology with a focus on new genetic and molecular discoveries. New classifications will be elucidated, and management will be updated in broad strokes. Illustrative pathology slides will be used as appropriate. It is critical for the reader to realize from the outset that terminology such as focal segmental glomerulosclerosis and crescentic glomerulonephritis represent a pattern of injury rather than a specific disease. Whenever possible, the specific etiology and pathogenesis of a given pattern should be sought. It is also important to know that the same disease or mechanism can cause multiple patterns of injury, whereas the same pattern of injury can be the result of multiple disease or mechanisms.
Article published online:
04 August 2021
© 2020. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Sethi S, Haas M, Markowitz GS, D’Agati VD, Rennke HG, Jennette JC. et al. Mayo clinic/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol 2016; 27: 1278-87
- 2 Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis–a new look at an old entity. N Engl J Med 2012; 366: 1119-31
- 3 Zipfel PF, Wiech T, Rudnick R, Afonso S, Person F, Skerka C. Complement inhibitors in clinical trials for glomerular diseases. Front Immunol 2019; 10: 2166
- 4 King C, Logan S, Smith SW, Hewins P. The efficacy of rituximab in adult frequently relapsing minimal change disease. Clin Kidney J 2017; 10: 16-9
- 5 Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J. et al. Rituximab for minimal-change nephrotic syndrome in adulthood: Predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant 2014; 29: 2084-91
- 6 Kruzel-Davila E, Wasser WG, Skorecki K. APOL1 nephropathy: A population genetics and evolutionary medicine detective story. Semin Nephrol 2017; 37: 490-507
- 7 Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Radin M. et al. High-dose rituximab ineffective for focal segmental glomerulosclerosis: A long-term observation study. Am J Nephrol 2017; 46: 108-13
- 8 Beck Jr LH, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD. et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
- 9 Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: Time for a paradigm shift. Nat Rev Nephrol 2017; 13: 563-79
- 10 Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N. et al MENTOR Investigators. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381: 36-46
- 11 Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A. Acthar gel in the treatment of nephrotic syndrome: A multicenter retrospective case series. BMC Nephrol 2016; 17: 37
- 12 Mestecky J, Novak J, Moldoveanu Z, Raska M. IgA nephropathy enigma. Clin Immunol 2016; 172: 72-7
- 13 Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M. et al. Oxford classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int 2017; 91: 1014-21
- 14 Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B. et al STOP-IgAN Investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373: 2225-36
- 15 Jennette JC. Overview of the 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Clin Exp Nephrol 2013; 17: 603-6
- 16 Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 2017; 12: 1680-91
- 17 Geetha D, Jin Q, Scott J, Hruskova Z, Hanouneh M, Little MA. et al. Comparisons of guidelines and recommendations on managing antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep 2018; 3: 1039-49
- 18 Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB. et al International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-30
- 19 Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD. et al American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808
- 20 Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z. et al. Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med 2015; 162: 18-26